Understand · Treat · Recover
Prognosis, Survival and Frequently Asked Questions
Statistics can describe groups, but an individual outlook depends on stage, biology, health, treatment and response.
For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.
This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.
Chapter 20 of 20
How stage influences outlook
Stage I disease generally offers the strongest chance of cure. Stages II and III may also be treated with curative intent, often using combined therapy; deeper invasion and more involved nodes increase recurrence risk. Gastric stage IV disease usually needs a control-focused plan. For GEJ cancers, confirm whether gastric or esophageal staging is being used before interpreting a stage label.
Population statistics with their limits
| US SEER summary stage | Five-year relative survival |
|---|---|
| Localized | 78.1% |
| Regional | 39.0% |
| Distant | 8.1% |
Source: US SEER 21 excluding Illinois, diagnoses 2016–2022, all races and both sexes, as displayed on the source page checked 21 October 2026. These are stomach-cancer summary-stage groups, not exact TNM stages I–IV and not a GEJ-specific prediction. Relative survival compares survival with the expected survival of a comparable general population. Country, screening, tumour mix and treatments affect outcomes; newer therapies may not be fully reflected.
Why complete removal matters
An R0 operation is an important component of a potentially curative pathway, but it cannot guarantee that microscopic disease is absent elsewhere. Histology, nodal burden, response to preoperative therapy, fitness and ability to recover also matter. Ask the team for a range and the reasons behind it rather than a precise personal deadline.
What biomarkers can change
HER2 positivity creates treatment opportunities; it is not a simple good-or-bad prognosis label. PD-L1 CPS helps select certain immune treatments. MSI-high/dMMR disease can be particularly sensitive to immunotherapy. CLDN18.2 is a surface protein used to select zolbetuximab in a defined advanced-disease setting. None guarantees response, and eligibility differs between curative and metastatic treatment.
Common practical questions
Many people can live actively without a stomach with adapted meals and nutrient replacement. Most gastric cancers are not inherited, but selected histories warrant genetics assessment. H. pylori contributes to risk and should be managed appropriately; eradication does not replace cancer treatment. Cancer does not always return after curative treatment. If chemotherapy stops working, reassessment can identify another line, a trial or a better symptom-focused plan.
Discussing the future compassionately
Some people want detailed numbers; others prefer broad expectations. Both preferences are valid. Ask what treatment is most likely to achieve, how soon benefit should appear and which findings would change the plan. Early palliative care supports comfort, communication and family needs alongside active treatment. Planning ahead can preserve choices without taking away hope.
Key takeaways
Use statistics to support informed choices, never to assign an individual deadline.
Frequently asked questions
Can stomach and GEJ cancers be cured?
Yes, particularly when localised and completely treatable. Cure is not guaranteed even after successful surgery.
Can stage IV cancer still be treated?
Yes. Systemic treatments can improve control and survival in suitable patients, with supportive care throughout.
Can immunotherapy improve survival?
Yes, in defined populations and regimens. Benefit depends on tumour biology and the treatment setting.
What if chemotherapy does not work?
Confirm progression, reassess biomarkers and fitness, and discuss other therapies, trials and symptom-focused care.
Does a five-year figure mean someone has five years to live?
No. It is a group statistic measured at a time point, not an expiry date.
Does cancer always return?
No. Some people remain cancer-free long term.
When should palliative care begin?
Whenever symptoms, emotional distress or complex decisions warrant it; early involvement is particularly helpful in advanced disease.
What is the most useful question at a consultation?
Ask what the next treatment is intended to achieve and how its benefits and burdens will be assessed.